ASGCT News

FilterBy

FDA Approves Zolgensma, Landmark AAV-Delivered Gene Therapy to Treat Spinal Muscular Atrophy

Zolgensma (Novartis, AveXis), an AAV-delivered gene therapy used to treat spinal muscular atrophy (SMA) also known as AVXS-101, was approved for clinical use in the United States by the Food and Drug Administration today. 

ASGCT Heats Up in Summer 2019
June 14, 2019
Advocacy ASGCT News

Up-to-date clinical trials info and a new policy-centered event keep up the post-meeting momentum.

FDA Approves Zolgensma, Landmark AAV-Delivered Gene Therapy to Treat Spinal Muscular Atrophy

Zolgensma (Novartis, AveXis), an AAV-delivered gene therapy used to treat spinal muscular atrophy (SMA) also known as AVXS-101, was approved for clinical use in the United States by the Food and Drug Administration today. 

22nd Annual Meeting Recap
May 16, 2019
Annual Meeting 2019

Edith Pfister, Ph.D., associate editor of ASGCT's newsletter The Vector, not only attended the record-breaking ASGCT 22nd Annual Meeting but presented an abstract on the meeting's final day. Read about her experience and recap an incredible week of science.

The Case for Growth

Following a record-breaking ASGCT Annual Meeting, the Society is ready to branch out and ensure its growth is sustainable.

Scientific Leaders Call For Global Moratorium on Germline Gene Editing
April 24, 2019
Advocacy Policy Updates

In a letter sent to U.S. Department of Health and Human Services Secretary Alex Azar today, a broad collective of 62 individual scientists, bioethicists, and biotechnology executives, including past-presidents and current board of directors members from ASGCT, across industry and academia called for collaboration on a binding global moratorium on human clinical germline experimentation.

2019
ASGCT Policy Summit
November 4 – 6 | Washington D.C.
Close